Systematic profiling of antigen bias in humoral response against SARS-CoV-2

• Published in: Virus research 2022-04, Vol.312, p.198711-198711, Article 198711
• Main Authors: Wei, Nana, Wang, Qiujing, Lin, Zhibing, Xu, Liyun, Zhang, Zheen, Wang, Yan, Yang, Zhejuan, Li, Lue, Zhao, Tingxiao, Wang, Lu, Lou, Haifei, Han, Mingfang, Ma, Mingliang, Jiang, Yaosheng, Lu, Jinmiao, Zhu, Shilan, Cui, Li, Li, Shibo
• Format: Article
• Language: English
• Subjects: Antibodies; Antibodies, Viral; Antigen bias; COVID-19; COVID-19 Vaccines; Epitopes; Humans; Immunity, Humoral; Proteome microarray; SARS-CoV-2; Spike Glycoprotein, Coronavirus
• ISSN: 0168-1702; 1872-7492
• DOI: 10.1016/j.virusres.2022.198711

•All these patients even at 12 months after onset had IgG and IgM antibodies.•Multiple peptides identified were able to be recognized by most of the sera isolated from both AS and S patients, and three peptides located in RBD.••Five epitopes exhibited strong discriminatory ability between the AS and s patients, and were identified to be associated with the clinical adverse events. We know little about the antigen bias in SARS-CoV-2 humoral response and the epitopes of spike recognized by the immune system in asymptomatic (AS) patients and symptomatic (S) patients. Here, we used a microarray to evaluate the humoral immune response in the sera collected from 33 COVID-19-recovered patients up to 1 year. We found that the levels of IgG and IgM induced by the 23 proteins differed significantly in the same patients, and were able to distinguish AS and S patients. The N- and S-specific antibodies were detected even at 12 months after onset. Five epitopes were identified to be associated with the clinical adverse events, and three peptides located in RBD. Overall, this study presents a systemic view of the SARS-CoV-2 specific IgG and IgM responses between AS and S recovered patients and provide insights to promote precise development of SARS-CoV-2 vaccines.